PR Newswire Clinical TrialsOriginal article
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
Phase 1positiveGLIX1olaparibPositive
AI Analysis
Summary
BioLineRx and Hemispherian announced preclinical data showing GLIX1 has a strong synergistic effect when combined with olaparib in ovarian cancer xenograft models, with substantially better efficacy than each drug alone.
Outcome Details
Preclinical data demonstrated strong synergistic effect between GLIX1 and olaparib in patient-derived ovarian cancer xenograft model with substantially better efficacy compared to control and single agents
Importance:3/10
Sentiment:
0.70
preclinicalcombination therapyPARP inhibitorovarian cancersynergy
Read the original article
Published by PR Newswire Clinical Trials on July 8, 2026 11:00 AM